dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Duct Cell Adenocarcinoma of the Pancreas
Conditions
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Mar 1, 2015 → —
NCT ID
NCT02048943About dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation
dovitinib lactate + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation is a phase 1 stage product being developed by Novartis for Duct Cell Adenocarcinoma of the Pancreas. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02048943. Target conditions include Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02048943 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Duct Cell Adenocarcinoma of the Pancreas